Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Kinetics of Blood Platelets Transfused to Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03561909
Recruitment Status : Completed
First Posted : June 19, 2018
Last Update Posted : May 10, 2019
Sponsor:
Collaborators:
Larix A/S
Fraunhofer Institute for Molecular Biology and Applied Ecology
German Red Cross
Bioscientia Central Laboratory
Information provided by (Responsible Party):
Prophylix Pharma AS

Brief Summary:

The current phase 0 trial is preceding the phase 1/2 trial of a newly developed drug, NAITgam, for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) - a rare, but potentially very severe bleeding condition in the fetus or newborn. FNAIT may occur in women whose blood platelets do not express HPA-1a. If the fetus has inherited HPA-1a from the father, the mother's immune system may be stimulated to produce HPA-1a antibodies if HPA-1a positive fetal blood platelets enter the maternal circulation during delivery. In a subsequent pregnancy, such antibodies will cross the placenta and may reduce the number of HPA-1a positive blood platelets in the fetus, which in turn may result in severe bleeding in the fetus or newborn.

The phase 1/2 study of NAITgam will examine NAITgam's ability to eliminate HPA-1a positive blood platelets that has been transfused to healthy male subjects, whose blood platelet do not express HPA-1a. The ability to quickly eliminate transfused HPA-1a positive platelets is considered as a surrogate endpoint for NAITgam's ability to prevent formation of antibodies against HPA-1a after delivery of an HPA-1a positive child.

The current phase 0 trial will examine the survival of blood platelets transfused to healthy male individuals without subsequent administration of NAITgam. The natural survival of transfused platelet, as determined in the phase 0 trial, will be compared with the survival of transfused HPA-1a positive platelets after administration of NAITgam in the phase 1/2 trial. The aim of the phase 0 trial is first, to determine the dose of blood platelet that should be transfused to the healthy subjects in the phase 1/2 trial; and secondly, to determine the optimal time point, after transfusion of platelets, for administration of NAITgam in the phase 1/2 trial.

Eight to 24 healthy male subjects will be included in the phase 0 trial. After transfusion of platelets, blood samples will be collected at regular intervals to determine the proportion of transfused blood platelets. Differences between tissue type antigens between donor and recipient will be used to determine the proportion of transfused platelets. Survival of transfused platelets will be performed by flow cytometry - a method that can be used to quantify very small proportions of cells in the blood. Fluorochrome-conjugated monoclonal antibodies against HLA-A2 and HLA-A9 will be used for flow cytometric identification the transfused platelets.


Condition or disease Intervention/treatment Phase
Fetal and Neonatal Alloimmune Thrombocytopenia Other: Platelet transfusion Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-label, Single Centre, Exploratory Trial Investigating the Kinetics of Platelets Transfused to Healthy, Male Subjects
Actual Study Start Date : April 17, 2018
Actual Primary Completion Date : December 10, 2018
Actual Study Completion Date : December 10, 2018


Arm Intervention/treatment
Platelet transfusion
HLA-A2 and/or HLA A9 negative healthy study subjects will be transfused with a small dose of platelets from an HLA-A2 and/or HLA-A9 positive donor.
Other: Platelet transfusion
Transfusion of a platelet dose from 20 × 10ˆ9 to 100 × 10ˆ9.




Primary Outcome Measures :
  1. Terminal elimination half live [ Time Frame: The terminal elimination half live of transfused platelets will be determined based on the survival of platelets within the first 5 days after trandfusion ]
    Determination of the terminal elimination half live of a single platelet dose transfused to healthy male subjects


Secondary Outcome Measures :
  1. Cmax [ Time Frame: Will be determined within the first 5 days after transfusion ]
    The peak platelet concentration

  2. AUC [ Time Frame: Will be determined within the first 5 days after transfusion ]
    The area under the platelet concentration versus time curve

  3. Clearance [ Time Frame: Will be determined within the first 5 days after transfusion ]
    Natural clearance of platelets from the circulation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Written informed consent must be obtained before any trial related procedures are performed
  2. Healthy, male subjects
  3. Age ≥18 and < 50 years old
  4. BMI < 30kg/mˆ2
  5. HLA-A2 and/or HLA-A9 negative

Exclusion Criteria:

  1. History of hypersensitivity to platelet concentrates or human plasma protein
  2. Subjects with known IgA deficiency and anti-IgA antibodies
  3. Blood donation received within 3 weeks
  4. Platelet counts < 150 × 10ˆ9/L or > 450 × 10ˆ9/L
  5. Any type of known platelet function disorder
  6. Treatment with non-steroidal anti-inflammatory drugs (NSAIDs, e.g. acetylsalicylic acid) or selective serotonin reuptake inhibitors within 7 days prior to Visit 1
  7. Chronic or ongoing active infectious disease requiring systemic treatment including, but not limited to, chronic and renal infection, chronic chest infection with bronchiectasis, and tuberculosis
  8. Participation in any other interventional clinical trial during the trial period
  9. Subjects known or suspected of not being able to comply with this trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
  10. Presence of HLA-antibodies class I (MFI level > 3000)
  11. Signs of previous or ongoing infection with HIV and/or Hepatitis B and/or C virus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03561909


Locations
Layout table for location information
Germany
Fraunhofer Institute for Molecular Biology and Applied Ecology IME
Frankfurt am main, Hessia, Germany, 60596
Sponsors and Collaborators
Prophylix Pharma AS
Larix A/S
Fraunhofer Institute for Molecular Biology and Applied Ecology
German Red Cross
Bioscientia Central Laboratory
Investigators
Layout table for investigator information
Study Chair: Jens Kjeldsen-Kragh, MD, PhD Prophylix Pharma AS
Principal Investigator: Michaela Köhm, MD Fraunhofer Institute for Molecular Biology and Applied Ecology IME

Layout table for additonal information
Responsible Party: Prophylix Pharma AS
ClinicalTrials.gov Identifier: NCT03561909     History of Changes
Other Study ID Numbers: PX-0
First Posted: June 19, 2018    Key Record Dates
Last Update Posted: May 10, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombocytopenia
Thrombocytopenia, Neonatal Alloimmune
Blood Platelet Disorders
Hematologic Diseases
Infant, Newborn, Diseases